Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells

ASN Neuro

Volumn 6, Issue 3, 2014, Pages 171-183

  Lisi, Lucia ^a   Stigliano, Egidio ^a   Lauriola, Libero ^a   Navarra, Pierluigi ^a   Dello Russo, Cinzia ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Arginase; Glioma; IL 10; Microglia; Microglial polarization; mTOR; NOS

Indexed keywords

ARGINASE; DICHLORODIHYDROFLUORESCEIN DIACETATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MAMMALIAN TARGET OF RAPAMYCIN; CD68 ANTIGEN, HUMAN; CULTURE MEDIUM; DIFFERENTIATION ANTIGEN; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICROGLIA; PHASE CONTRAST MICROSCOPY; PHENOTYPE; POLARIZATION; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; CELL CULTURE; CLASSIFICATION; CULTURE MEDIUM; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GLIA; GLIOMA; METABOLISM; NEWBORN; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; RAT; TIME; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARGINASE; CELL PROLIFERATION; CELLS, CULTURED; CEREBRAL CORTEX; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOMA; HUMANS; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MICROGLIA; NEUROGLIA; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; RATS; TIME FACTORS; UP-REGULATION;

EID: 84900428333     PISSN: None     EISSN: 17590914     Source Type: Journal    
DOI: 10.1042/AN20130045     Document Type: Article

References (33)

1. Boche D., Perry VH, Nicoll JA (2013) Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 39:3-18.
2. Bradley D., Rees J (2014) Updates in the management of high-grade glioma. J Neurol 261:651-651.
3. Carvalho da Fonseca AC, Badie B (2013) Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol 2013:264124.
4. Charles N. A, Holland EC, Gilbertson R, Glass R, Kettenmann H (2012) The brain tumor microenvironment. Glia 60:502-514.
5. Chhor V., Le Charpentier T, Lebon S, Oré MV, Celador IL, Josserand J, Degos V, Jacotot E., Hagberg H, Sävman K, Mallard C, Gressens P, Fleiss B (2013) Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 32:70-85.
6. Dello Russo C, Boullerne AI, Gavrilyuk V, Feinstein DL (2004) Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammation 1:9.
7. Dello Russo C, Lisi L, Tringali G, Navarra P (2009) Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol 78:1242-1251.
8. Ellert-Miklaszewska A, Dabrowski M, Lipko M, Sliwa M, Maleszewska M, Kaminska B. (2013) Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia 61: 1178-1190.
9. Gabrusiewicz K., Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B. (2011) Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One 6:e23902.
10. Gadani S. P, Cronk JC, Norris GT, Kipnis J (2012) IL-4 in the brain: a cytokine to remember. J Immunol 189:4213-4219.
11. Galvão R. P, Zong H (2013) Inflammation and gliomagenesis: bi-directional communication at early and late stages of tumor progression. Curr Pathobiol Rep 1:19-28.
12. Held-Feindt J, Hattermann K, Müerköster SS, Wedderkopp H, Knerlich-Lukoschus F, Ungefroren H, Mehdorn HM, Mentlein R (2010) CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res 316:1553-1566.
13. Hu X., Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J (2012) Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43:3063-3070.
14. Huysentruyt L. C, Akgoc Z, Seyfried TN (2011) Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme? ASN Neuro 3:4.
15. Kushchayev S. V, Kushchayeva YS, Wiener PC, Badie B, Preul MC (2012) Monocyte-derived cells of the brain and malignant gliomas: the double face of Janus. World Neurosurg, doi: 10.1016/j.wneu.2012.11.059.
16. LeBel CP, Ischiropoulos H, Bondy SC (1992) Evaluation of the probe 2_,7_-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 5:227-231.
17. Li W., Graeber MB (2012) The molecular profile of microglia under the influence of glioma. Neuro Oncol 14:958-978.
18. Lisi L., Navarra P, Feinstein DL, Dello Russo C (2011) The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation 8:1.
19. Markovic D. S, Glass R, Synowitz M, Rooijen Nv, Kettenmann H (2005) Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol 64: 754-762.
20. O'Brien ER, Howarth C, Sibson NR (2013) The role of astrocytes in CNS tumors: pre-clinical models and novel imaging approaches. Front Cell Neurosci 7:40.
21. Okada M., Saio M, Kito Y, Ohe N, Yano H, Yoshimura S, Iwama T, Takami T (2009) Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol 34:1621-1627.
22. Rivera-Zengotita M, Yachnis AT (2012) Gliosis versus glioma?: don't grade until you know. Adv Anat Pathol 19:239-249.
23. Roggendorf W., Strupp S, Paulus W (1996) Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 92:288-293.
24. Rolle C. E, Sengupta S, Lesniak MS (2012) Mechanisms of immune evasion by gliomas. Adv Exp Med Biol 746:53-76.
25. Rosner M., Siegel N, Valli A, Fuchs C (2010) Hengstschläger M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acid 38:223-228.
26. Schwartz M., Butovsky O, Brück W, Hanisch UK (2006) Microglial phenotype: is the commitment reversible? Trends Neurosci 29:68-74.
27. Stupp R., Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin S. K, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T., Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.
28. Stupp R., Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K., Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin S. K, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff R. O; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
29. Voisin P., Bouchaud V, Merle M, Diolez P, Duffy L, Flint K, Franconi JM, Bouzier-Sore AK (2010) Microglia in close vicinity of glioma cells: correlation between phenotype and metabolic alterations. Front Neuroenergetics 2:131.
30. Wen P. Y, Kesari S, Malignant gliomas in adults (2008) N Engl J Med. 359:492-507 [published erratum in: N Engl J Med. 2008 August 21;359:877].
31. Wolburg H., Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K (2012) The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 33:579-589.
32. Zhai H., Heppner FL, Tsirka SE (2011) Microglia/macrophages promote glioma progression. Glia 59:472-485.
33. Zhan C., Lu W (2012) The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr Pharm Biotechnol 13:2380-2387.